

PLATFORM OF LABORATORIES FOR ADVANCES IN CARDIAC EXPERIENCE

ROMA Centro Congressi di Confindustria Auditorium della Tecnica 9ª Edizione 30 Settembre 1 Ottobre 2022



Stratificazione del rischio e terapia nelle malattie neuromuscolari applicazione delle linee guida nella pratica clinica






Vincenzo Russo MD PhD MMSc



Myopathy	Gene	Heart involvement	Frequency of heart involvement	Ventricular arrhythmia	Atrial arrhythmia	Sudden death reported
Duchenne	Dystrophin	DCM	>90%	PVC	Only at late stage	Yes
Becker	Dystrophin	DCM	60–75%	VT associated with DCM	Associated with DCM	Yes
Myotonic, type 1	CGT repeat expansion	Conduction disease and DCM	60-80%	VT, ICD indicated	Age dependent	Yes, 30% of death
Myotonic, type 2	CGT repeat expansion	Conduction disease	10-25%	Uncommon	Uncommon	Yes
Emery-Dreifuss	Emerin, Iamin A and C	Conduction disease and DCM	>90%	VT, ICD indicated	Common, atrial standstill	Yes, 30% of death
Limb-girdle type IB	Lamin A and C	Conduction disease and DCM	>90%	VT, ICD indicated	Common	Yes, 30% of death
Limb-girdle type 2C-2F	Sarcoglycans	DCM	<25%	Uncommon	Limited data	Unknown
Limb-girdle type 21	Fukutin-related protein	DCM	20-80%	Uncommon	Not reported	Unknown
Facioscapulohumeral	D4Z4 repeat contraction	Conduction disease	5-15%	Rare VTs	Rare	No

Muscular Dystrophies are an heterogeneous group of inherited diseases characterized by muscular and cardiac involvement, that occurs as a degenerative process with fibrosis and fatty replacement of the myocardium









International Journal of Cardiology 207 (2016) 284-285



Contents lists available at ScienceDirect International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard



Correspondence

Sudden cardiac death in neuromuscolar disorders: Time to establish shared protocols for cardiac pacing



Vincenzo Russo *, Anna Rago, Gerardo Nigro

Chair of Cardiology, Second University of Naples - Monaldi Hospital, Italy




2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders @

William J. Groh, MD, MPH, FHRS (Chair),¹ Deepak Bhakta, MD, MBA, FHRS, FACC, FAHA, FACP, CCDS (Vice-Chair),² Gordon F. Tomaselli, MD, FHRS (Vice-Chair),³ Ryan G. Aleong, MD, FHRS,⁴ Ricardo Alkmim Teixeira, MD, PhD,^{5,*} Anthony Amato, MD,^{6,*} Samuel J. Asirvatham, MD, FHRS,⁷ Yong-Mei Cha, MD, FHRS,⁷ Domenico Corrado, MD, PhD, FESC,^{8,‡} Denis Duboc, MD, PhD,⁹ Zachary D. Goldberger, MD, FHRS, ¹⁰ Minoru Horie, MD, PhD, ^{11,§} Joseph E. Hornyak, MD, PhD, 12, John Lynn Jefferies, MD, MPH, FACC, FAHA, FHFSA, 13,# Stefan Kääb, MD, PhD, 14,‡ Jonathan M. Kalman, MBBS, PhD, FHRS, 15 Naomi J. Kertesz, MD, FHRS, CEPS-P, 16, ** Neal K. Lakdawala, MD, 6, †† Pier D. Lambiase, BCH, BM, MBChB, PhD, FHRS, 17, \$ Steven A. Lubitz, MD, MPH, 18, \$ Hugh J. McMillan, MD, MSc, 19,88 Elizabeth M. McNally, MD, PhD, 20,# Margherita Milone, MD, PhD,^{7,†} Narayanan Namboodiri, MBBS, MD,^{21,¶¶} Saman Nazarian, MD, PhD, FHRS, 22 Kristen K. Patton, MD, FHRS, 23 Vincenzo Russo, MD, PhD, 24, Frederic Sacher, MD, PhD, 25, # Pasquale Santangeli, MD, PhD,²² Win-Kuang Shen, MD, FHRS,²⁶ Dario C. Sobral Filho, MD, PhD, 27,## Bruce S. Stambler, MD, FHRS, 28 Claudia Stöllberger, MD,²⁹ Karim Wahbi, MD, PhD,⁹ Xander H.T. Wehrens, MD, PhD, FHRS, 30 Menachem Mendel Weiner, MD, 31,*** Matthew T. Wheeler, MD, PhD, 32,# Katja Zeppenfeld, MD, PhD 33,‡








Duchenne Muscular Dystrophy Becker Muscular Dystrophy Limb Girdle type 2 Muscular Dystrophy












The presence of systolic dysfunction was a powerful predictor of mortality but ECG abnormalities, late potentials or ventricular arrhythmias were not predictive



Corrado G et al. Am J Cardiol. 2002;89:838



ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies

Vincenzo Russo MD, PhD, MMSc^{a, *}, Andrea Antonio Papa MD^{a, b}, Emmanuel Ato Williams MD^c, Anna Rago MD^a, Alberto Palladino MD^b, Luisa Politano MD, PhD^b, Gerardo Nigro, MD, PhD^a

^a University of Campania "Luigi Vanvitelli", Monaldi Hospital, Naples, Italy

^b Cardiomyology and Genetic Section, Department of Internal and Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy

^c Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom

>Use of ACEI or ARB for all neuromuscular disorder patients with reduced systolic cardiac function and suggests to consider such treatment before the onset of reduced systolic cardiac function in boys with DMD age ≥ 10 .

≻The relatively low risk of usage of ACE-Is and ARBs should encourage the consideration of earlier therapy.





Pacemaker

1	B-NR	 In patients with DMD, BMD, or LGMD2 with documented symptomatic bradycardia due to any degree of sinus node dysfunction or AV block, permanent pacemaker implantation is indicated if concordant with the patient's goals of care and clinical status. 	79-82
1	B-NR	 In patients with DMD, BMD, or LGMD2 and third-degree or advanced second-degree AV block at any anatomical level, with or without symptoms, permanent pacemaker implantation is indicated if concordant with the patient's goals of care and clinical status. 	79-81


ICD

2a	B-NR	 In patients with DMD, BMD, or LGMD2 with an LVEF ≤35% despite guideline-directed medical therapy, ICD therapy is reasonable if concordant with the patient's goals of care and clinical status. 	68,97-99
----	------	---	----------



Major Effects of Myotonic Dystrophy Type 1

www.myotonicdystrophy.con



Low testosterone levels, erectile dysfuntion, testicular failure and gonadal altrophy.

Bone: Anomalies

Cardiovascular System: Heart condition abnormalities, arrhymias, cardiomyopathy

Gastrointestinal Tract: Swallowing issues, abdominal pain, irritable bowel syndrome, constipation/diarrhea, poor nutrition and weight loss, chronic infections


Muscle: Weakness, wasting (atropy), myotonia, pain

Reproductive System in Women: Weakened uterine muscle, pregnancy-related complications, and gynecological problems.





Cardiac involvement, often preceding the skeletal muscle one, occurs in 80% of DM1 patients and represents the second most common cause of death, after respiratory causes



Cardiac involvement is due to interstitial fibrosis and fatty replacement in the specialized conduction system and in both atria and ventricles



≻Atrio-Ventricular Blocks

- first degeee
- second degree
- third degree

➤Supraventricular Arrhytmias

- atrial fibrillation
- atrial flutter
- atrial tachycardia

➤Ventricular Dysfunction

>Ventricular Tachycardia





Petri H at al. Int J Cardiol 2012;160:82-88






Recommendations for diagnostic testing and risk stratification in myotonic dystrophy types 1 and 2						
COR	LOE	Recommendations	References			
1	C-EO	 Coordinated care of patients with DM1 or DM2 should be conducted in a medical setting where there is access to expertise in the neurological, cardiac, arrhythmic, pulmonary, and genetic manifestations of these disorders. 				
1	B-NR	 In patients with DM1 or DM2, cardiac evaluation including physical examination, ECG, ambulatory ECG, and cardiac imaging (echocardiography or CMR) at diagnosis with periodic retesting is recommended even in the absence of cardiac symptoms. 	24,26,104,106,108, 110,114,115			
1	C-LD	 In patients with DM1 or DM2 and cardiac conduction disorder, close monitoring for arrhythmic complications is recommended when using mexiletine (or other sodium channel blockers). 	116-119			














PR≥ 240 *ms*

QRS≥ *120 ms*





The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


Electrocardiographic Abnormalities and Sudden Death in Myotonic Dystrophy Type 1

William J. Groh, M.D., M.P.H., Miriam R. Groh, M.S., Chandan Saha, Ph.D., John C. Kincaid, M.D., Zachary Simmons, M.D., Emma Ciafaloni, M.D., Rahman Pourmand, M.D., Richard F. Otten, M.D., Deepak Bhakta, M.D., Girish V. Nair, M.D., M.S., Mohammad M. Marashdeh, M.D., Douglas P. Zipes, M.D., and Robert M. Pascuzzi, M.D.

Characteristic	Sudden De	ath	Death from Progressive Neuromuscular Respiratory Failure		Death from Any Cause	
	Relative Risk (95% CI)	P Value	Relative Risk (95% CI)	P Value	Relative Risk (95% CI)	P Value
Age†	1.16 (0.76–1.75)	0.50	1.81 (1.20-2.74)	0.005	1.46 (1.13-1.87)	0.003
Muscular-impairment score <u>‡</u>						
1 or 2			1.0		1.0	
3			1.28 (0.20-8.19)	0.80	1.13 (0.47-2.73)	0.79
4			2.85 (0.60-13.55)	0.19	1.47 (0.67-3.19)	0.33
5			13.07 (2.77–61.61)	0.001	4.54 (2.02-10.19)	<0.001
Heart failure			5.39 (1.46-19.82)	0.01	2.85 (1.20-6.74)	0.02
Atrial tachyarrhythmia	5.18 (2.28-11.77)	< 0.001	2.41 (1.10-5.31)	0.03	2.59 (1.55-4.32)	<0.001
Pacemaker	1.35 (0.51-3.56)	0.54	1.80 (0.77-4.20)	0.17	1.46 (0.82-2.60)	0.19
Ventricular tachyarrhyth- mia					6.41 (2.30–17.89)	<0.001
Severe ECG abnormality§	3.30 (1.24-8.78)	0.02	1.33 (0.53-3.33)	0.55	1.58 (0.90-2.81)	0.11

Groh *et al.* found that DM1 patients – even when asymptomatic – presenting with prolonged PR intervals (\geq 240 ms), wide QRS complex (\geq 120 ms), or atrial tachyarrhythmias were at higher risk of SCD when compared to those with normal ECGs





Because the risk of SCD most often appears to be associated to paroxysmal complete AV block, it has become common practice to implant a PM in DM1 patients when they have ECG abnormalities suggestive of advance conduction system disease, even if they are asymptomatic.

Groh WJ, N Engl J Med. 2008 Jun 19;358(25):2688-97





Table 3 Multiple variable analysis of association between baseline characteristics and clinical outcomes

European Heart Journal (2017) **38**, 751–758 doi:10.1093/eurheartj/ehw569 CLINICAL RESEARCH Heart failure/cardiomyopathy

Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1


Karim Wahbi^{1,2,3}, Dominique Babuty⁴, Vincent Probst⁵, Ludivine Wissocque⁶, Fabien Labombarda⁷, Raphaël Porcher⁸, Henri Marc Bécane², Arnaud Lazarus⁹, Anthony Béhin², Pascal Laforêt^{2,10}, Tanya Stojkovic², Nicolas Clementy⁴, Aurélie Pattier Dussauge^{5,11}, Jean Baptiste Gourraud⁵, Yann Pereon¹², Arnaud Lacour¹³, Françoise Chapon¹⁴, Paul Milliez⁷, Didier Klug⁶, Bruno Eymard^{2,10}, and Denis Duboc^{1,2,3}

	Overall surviva		Sudden death		Sustained ventr	icular	Major conducti	on
					tachyarrhythmi	a	defect	
	Adjusted HR (95% CI)	Р	Adjusted HR (95% CI)	P	Adjusted HR (95% CI)	Р	Adjusted HR (95% CI)	Р
Age, per year	1.07 (1.06-1.08)	< 0.0001	1.05 (1.02-1.08)	0.0006	20	62	1.02 (1.01-1.04)	0.0005
Male sex	1.47 (1.12-1.93)	0.005	-	-		-	1.49 (1.05-2.11)	0.024
Family history of sudden death	0.99 (0.63-1.57)	0.98	2.82 (1.21-6.53)	0.016	<u>11</u> 5	622	1.07 (0.58-1.95)	0.84
History of								
Coronary artery disease	0.72 (0.40-1.30)	0.27	1 <u>1</u> 10	_	2.77 (0.64-11.9)	0.17	0.68 (0.30-1.52)	0.35
Atrial fibrillation	0.99 (0.69-1.42)	0.95	1.69 (0.76-3.77)	0.20	2.46 (0.89-6.77)	0.081	2.12 (1.41-3.17)	0.0003
Ventricular tachycardia								
Non-sustained	0.94 (0.45-1.96)	0.86	2.36 (0.69-8.08)	0.17	8.57 (2.59-28.3)	0.0004	1.86 (0.91-3.80)	0.090
Sustained	1.65 (0.51-5.33)	0.40	_	_	2.13 (0.36-12.7)	0.41	_	-
Major conduction defect	1.30 (0.65-2.62)	0.46	-	-		-	-	-
Syncope	1.60 (1.13-2.28)	0.008	<u>1</u> 20	-	1 <u>0</u> 15	622	2.39 (1.61-3.56)	< 0.000
Heart rate, per 10 bpm	1.17 (1.08-1.26)	< 0.0001	1.16 (0.97-1.39)	0.099	-		1.10 (0.98-1.24)	0.095
1 st degree atrioventricular block	1.73 (1.31-2.28)	0.0001	1.55 (0.79-3.04)	0.21	1.37 (0.54-3.48)	0.51	1.60 (1.12-2.30)	0.010
Bundle branch block				0.012	1.78 (0.57-5.55)	0.32	1.85 (1.18-2.91)	0.007
Left	1.40 (0.98-2.01)	0.063	2.57 (1.23-5.37)					0.010
Right	1.27 (0.84–1.93)	0.26	-	-	-		1.91 (1.17-3.11)	
Left ventricular ejection fraction <50%	1.06 (0.64–1.75)	0.82	0.93 (0.27–3.17)	0.90	1.92 (0.57–6.50)	0.30	1.59 (0.90–2.79)	0.11

CI = confidence interval; HR = hazard ratio.


Age, family history of SD and LBBB were independent predictors of SD












PR> 200 ms

QRS> 100 ms


PLACE CALL CONTRACT A CALL CONTRACT A CALL CONTRACT

K	$\overline{\mathbf{N}}$		
-2			Z
Ų	~4	1	$\langle \cdot \rangle$

2a B-NR	4. In patients with DM1 or DM2 with symptoms consistent with bradycardia and with ECG evidence of mild to moderate conduction disorder and when noninvasive testing is nondiagnostic, electrophysiological testing is reasonable for risk stratification for AV block and sudden cardiac death.	26,120-123
---------	---	------------







2a	B-NR	 In patients with DM1 or DM2 with HV interval ≥70 ms on electrophysiological study, permanent pacemaker implantation is reasonable if concordant with the patient's goals of care and clinical status. 	120,123-126
----	------	---	-------------




JAMA The Journal of the American Medical Association



JAMA. 2012 Mar 28;307(12):1292-301. doi: 10.1001/jama.2012.346.

Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease.

<u>Wahbi K, Meune C, Porcher R, Bécane HM, Lazarus A, Laforêt P, Stojkovic T, Béhin A, Radvanvi-Hoffmann H, Evmard B, Duboc D</u>. Pierre et Marie Curie-Paris 6 University, Myology Institute, Pitié-Salpêtrière Hospital, 75013 Paris, France. karim.wahbi@cch.aphp.fr





Article in Press

Role of electrophysiological evaluation for the best device choice to prevent sudden cardiac death in patients with Myotonic Dystrophy Type 1 and Emery Dreifuss Muscular Dystrophy

Vincenzo Russo M, Luisa Politano, Gerardo Nigro



www.tcmonline.org







Pacemaker and Implantable Cardioverter-Defibrillator Use in a US Myotonic Dystrophy Type 1 Population

DEEPAK BHAKTA, M.D.,* CHANGYU SHEN, Ph.D.,† JACK KRON, M.D.,‡ ANDREW E. EPSTEIN, M.D.,§ ROBERT M. PASCUZZI, M.D.,¶ and WILLIAM J. GROH, M.D., M.P.H.*

In the largest registry published to date, 406 DM1 were followed for 9.5 years; forty-six patients received pacemakers for conduction abnormalities and twenty one patients received ICDs primarily for LV dysfunction. During follow-up period the authors showed seven sudden cardiac deaths in the pacemaker group, and 6.5% of patients had sudden death due to ventricular tachyarrhythmias compared with no patients in the group who received ICDs.

For the high risk of VT/VF and sudden death the ICDs rather than pacemakers should be considered for these patients.

B. Bhakta et al. J Cardiovasc Electrophysiol 22 (2011) 1369-1375






1	B-NR	4. In patients with DM1 or DM2 in whom clinically relevant ventricular arrhythmias are induced during electrophysiological study, ICD therapy is recommended if concordant with the patient's goals of care and clinical status.	110,124-126,132,133
2b	B-NR	 In patients with DM1 or DM2 in whom permanent pacemaker implantation is indicated, ICD therapy may be considered if concordant with the patient's goals of care and clinical status. 	106,121,132









JOURNAL ARTICLE

Arrhythmic CArdiac DEath in MYotonic dystrophy type 1 patients (ACADEMY 1) study: the predictive role of programmed ventricular stimulation


 $\mathsf{Get}\,\mathsf{access}\, \, > \,$

Vincenzo Russo, Andrea Antonio Papa ख़, Anna Rago, Carmine Ciardiello, Anna Maria Martino, Alessandra Stazi, Paolo Golino, Leonardo Calò, Gerardo Nigro

EP Europace, Volume 24, Issue 7, July 2022, Pages 1148–1155,

https://doi.org/10.1093/europace/euab282





Low positive predictive value (16%) and sensitivity (44%) High negative predictive value (90%) and specificity (67%)










LMNA-related Myopathies: Cardiac Arrhythmias



Patients with cardiolaminopathies may present a wide range of arrhythmic disorders, which include either:

Bradyarrhythmias Atrial fibrillation Ventricular tachyarrhtymias


in variable combinations, and with frequent association with left ventricular dysfunction and heart failure





≻Ventricular Tachyarrhythmias (VT/VF) can also occur in the early phase of the disease, before and independently of the development of ventricular dilatation.

Sudden death can be the first manifestation in some cases of VT/VF








ICD

1	B-NR	3. In patients with EDMD or LGMD1B with at least one of the following: second-degree or third-degree AV block, PR interval ≥230 ms, or spontaneous HV ≥70 ms, ICD therapy is recommended if concordant with the patient's goals of care and clinical status.	141,148,161-163
---	------	--	-----------------

1	B-NR	 In patients with EDMD or LGMD1B in whom clinically relevant ventricular arrhythmias are induced during electrophysiological study, ICD therapy is recommended if concordant with the patient's goals of care and clinical status. 	124-126,141,155
---	------	---	-----------------









Europace (2014) **16**, 563–571 doi:10.1093/europace/eut291 CLINICAL RESEARCH Channelopathies

Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive subjects

Nina E. Hasselberg^{1,2,3}, Thor Edvardsen^{1,2,3}, Helle Petri⁴, Knut E. Berge⁵, Trond P. Leren⁵, Henning Bundgaard⁴, and Kristina H. Haugaa^{1,2,3*}

¹Dept of Cardiology and Center for Cardiological Innovation. Oxlo University Hospital, Rischospitalet, Oxlo, Norway; ²University of Oxlo, Norway; ³Institute for Surgical Research, Oxlo University Hospital, Rischospitalet, Oxlo, Norway; ⁴The Unit for Inherited Cardiac Diseases, The Heart Centre, National University Hospital, Rightspitalet, Colo, Norway; ⁴Unit for Cardiolagy and Cardiovascular Genetics, Oxlo University Hospital, Rischospitalet, Rolo, Norway;

Prolonged PR-interval was the best predictor of Ventricular Arrhythmias in LMNA mutation-positive subjects.

Prolonged PR-interval was associated with VA, reduced myocardial function and septal fibrosis in Lamin A/C mutation-positive subjects.





ICD

2a B-NR 6. In patier reasonal





Journal of the American College of Cardiology © 2012 by the American College of Cardiology Foundation Published by Elsevier Inc. Vol. 59, No. 5, 2012 ISSN 0735-1097/\$36.00 doi:10.1016/j.jacc.2011.08.078

Genetic Disorders

Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers

A European Cohort Study

Ingrid A. W. van Rijsingen, MD,† Eloisa Arbustini, MD,|| Perry M. Elliott, MD,¶ Jens Mogensen, MD, PHD,# Johanna F. Hermans-van Ast, MS, PHD,* Anneke J. van der Kooi, MD, PHD,‡ J. Peter van Tintelen, MD, PHD,*** Maarten P. van den Berg, MD, PHD,*† Andrea Pilotto, BS,|| Michele Pasotti, MD, PHD,|| Sharon Jenkins, MS,¶ Camilla Rowland, MD,¶ Uzma Aslam, MS,‡‡ Arthur A. M. Wilde, MD, PHD,*† Andreas Perrot, MS,§§ Sabine Pankuweit, PHD,||| Aeilko H. Zwinderman, MS, PHD,§ Philippe Charron, MD, PHD,‡‡ Yigal M. Pinto, MD, PHD*†

LMNA mutation carriers presenting with at least two of these four risk factors *Non-sustained VT, LVEF <45%, Male sex, Non-missense mutations* were at high risk to develop malignant ventricular arrhythmias PLACE CONTRACTOR OF States

COR	LOE	Recommendations	References
1	C-EO	 In patients with NMDs who are considering or have a pacemaker or ICD, education on function including deactivation should be periodically discussed with the patient, their family members, and/or health care decision makers. 	
1	C-EO	 In patients with NMDs in whom the presence of conduction disorder portends a risk of ventricular arrhythmias, the decision of whether to implant a pacemaker or ICD should be concordant with the patient's overall medical care goals and clinical status. 	
1	C-EO	 In patients with NMDs who are considering ICD replacement and are undertaking advanced care planning, discussing the options of deferring ICD replacement is recommended. 	
1	C-EO	 In patients with NMDs who have an ICD and are undertaking advanced care planning, discussing the option of deactivation of ICD shock therapy is recommended. 	
1	C-EO	 In patients with NMDs who have an ICD and are experiencing ventricular arrhythmias with shocks refractory to available therapies, discussion of management of ICD therapy including shock deactivation is recommended, with careful attention to the patient's goals of care. 	
2a	C-EO	6. In patients with NMDs who have a pacemaker or ICD and are nearing the end of life, if the patient or their health care decision maker requests pacing inactivation, it is reasonable to comply after education on the consequences of inactivation, with careful attention to the patient's goals of care.	



PLATFORM OF LABORATORIES FOR ADVANCES IN CARDIAC EXPERIENCE

ROMA Centro Congressi di Confindustria Auditorium della Tecnica 9ª Edizione 30 Settembre 1 Ottobre 2022



GRAZIE PER L'ATTENZIONE vincenzo.russo@unicampania.it

Università degli Studi della Campania Luigi Vanvitelli



Vincenzo Russo MD PhD MMSc